Latest From Epistem PLC
Do it once, do it right and do it quick: when it comes to diagnostic testing, that suits patients and payer systems that are pursuing budget-sensitive, quality-driven health care solutions. It could also be the shorthand mission statement of POC diagnostics developer Atlas Genetics, which is developing a new IVD platform technology for infectious disease tests.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
- Gene Therapy, Cell Therapy
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Epistem PLC
- Senior Management
David Budd, CEO
John Rylands, Dir., Fin.
Catherine Booth, PhD, Managing Dir., Contract Rsch. Services
- Contact Info
Phone: (44) 161 606 7258
48 Grafton St.
Manchester, M19 9XX
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.